SCHEMBL220914

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

	Compound	similarity	top predicted	shared targets
	SCHEMBL221757	0.86	—	—
	SCHEMBL222323	0.80	NPC1 (0.50)	SMN1; SMN2NPC1RAB9A
	SCHEMBL13269681	0.79	ABL1 (0.44)	—
	SCHEMBL2739711	0.78	NPC1 (0.48)	SMN1; SMN2NPC1RAB9A
	SCHEMBL2739706	0.78	NPC1 (0.50)	SMN1; SMN2NPC1RAB9A
	SCHEMBL2739774	0.78	—	—
	SCHEMBL220204	0.78	—	—
	SCHEMBL2739669	0.78	NPC1 (0.47)	SMN1; SMN2NPC1RAB9APIK3CAPIK3CG
	SCHEMBL223019	0.78	—	—
	SCHEMBL2739827	0.76	ABL1 (0.49)	—

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.